https://healthandpharma.net/fda-designation-dubodencel-doc1021-cutaneous-melanoma Health and Pharma en 2026-05-07T00:00:00+00:00 FDA Grants Fast Track Designation to Dubodencel for Advanced Cutaneous Melanoma https://healthandpharma.net/rnase-h2-exposes-triple-breast-cancer Health and Pharma en 2026-05-06T00:00:00+00:00 Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer https://healthandpharma.net/fda-taletrectinib-ibtrozi-snda-ros1-lung-cancer Health and Pharma en 2026-05-06T00:00:00+00:00 FDA Accepts IBTROZI sNDA After Durable Long-Term Benefit in Advanced ROS1+ Lung Cancer